Home World News EMA Recommends Granting a Marketing Authorisation for Camizestrant World News EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 259 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... December 14, 2023 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients... July 9, 2026 FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for... October 28, 2026 Load more HOT NEWS Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... Gut Microbes May Influence How Well Radiation Therapy Works against Cancer Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic...
